Kyuichi Kadota1, Daniel Buitrago2, Ming-Ching Lee3, Jonathan Villena-Vargas2, Camelia S Sima4, David R Jones2, William D Travis5, Prasad S Adusumilli6. 1. Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, United States; Department of Diagnostic Pathology, Faculty of Medicine, Kagawa University, Kagawa, Japan. 2. Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States. 3. Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States; Institute of Clinical Medicine; National Yang-Ming University, Taipei, Taiwan. 4. Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States. 5. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, United States. 6. Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, United States. Electronic address: adusumip@mskcc.org.
Abstract
OBJECTIVE: CD10 (neutral endopeptidase) is expressed in various normal and tumor cells, and its biological function can be controlled through enzymatic activity and signaling pathways. We investigated whether CD10 expression predicted disease recurrence and whether it correlated with histologic subtypes of stage I lung adenocarcinoma. MATERIALS AND METHODS: We reviewed tumor slides of resected pathologic stage I lung adenocarcinomas (1995-2009). Tumors were classified according to the IASLC/ATS/ERS classification. CD10 immunohistochemistry was performed using tissue microarrays (n=915). We combined the intensity (0-3) and distribution scores (0-2) for CD10 to create a total score (0-5). Risk of recurrence was estimated using competing risks methods. RESULTS: In the training cohort (n=313), risk of recurrence of patients with high tumoral CD10 (score>1, n=57) was significantly higher (5-year cumulative incidence of recurrence [CIR], 37%) than in those with low CD10 (score≤1; n=256; 5-year CIR, 16%; P<0.001); this finding was confirmed in the validation cohort (n=602, P=0.036). High tumoral CD10 was associated with higher risk of recurrence in acinar (P=0.007) and papillary predominant tumors (P=0.022). High tumoral CD10 was most frequently identified in micropapillary predominant (41%) and solid predominant tumors (34%). On multivariate analysis of intermediate-grade tumors, high tumoral CD10 remained a significant independent risk factor of recurrence (hazard ratio, 1.88; P=0.025). CONCLUSION: In stage I lung adenocarcinoma, tumoral CD10 correlated with high-grade histology and was an independent predictor of recurrence in intermediate-grade tumors.
OBJECTIVE:CD10 (neutral endopeptidase) is expressed in various normal and tumor cells, and its biological function can be controlled through enzymatic activity and signaling pathways. We investigated whether CD10 expression predicted disease recurrence and whether it correlated with histologic subtypes of stage I lung adenocarcinoma. MATERIALS AND METHODS: We reviewed tumor slides of resected pathologic stage I lung adenocarcinomas (1995-2009). Tumors were classified according to the IASLC/ATS/ERS classification. CD10 immunohistochemistry was performed using tissue microarrays (n=915). We combined the intensity (0-3) and distribution scores (0-2) for CD10 to create a total score (0-5). Risk of recurrence was estimated using competing risks methods. RESULTS: In the training cohort (n=313), risk of recurrence of patients with high tumoral CD10 (score>1, n=57) was significantly higher (5-year cumulative incidence of recurrence [CIR], 37%) than in those with low CD10 (score≤1; n=256; 5-year CIR, 16%; P<0.001); this finding was confirmed in the validation cohort (n=602, P=0.036). High tumoral CD10 was associated with higher risk of recurrence in acinar (P=0.007) and papillary predominant tumors (P=0.022). High tumoral CD10 was most frequently identified in micropapillary predominant (41%) and solid predominant tumors (34%). On multivariate analysis of intermediate-grade tumors, high tumoral CD10 remained a significant independent risk factor of recurrence (hazard ratio, 1.88; P=0.025). CONCLUSION: In stage I lung adenocarcinoma, tumoral CD10 correlated with high-grade histology and was an independent predictor of recurrence in intermediate-grade tumors.
Authors: T Tokuhara; M Adachi; H Hashida; H Ishida; T Taki; M Higashiyama; K Kodama; S Tachibana; S Sasaki; M Miyake Journal: Jpn J Thorac Cardiovasc Surg Date: 2001-08
Authors: William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim R Geisinger; Yasushi Yatabe; David G Beer; Charles A Powell; Gregory J Riely; Paul E Van Schil; Kavita Garg; John H M Austin; Hisao Asamura; Valerie W Rusch; Fred R Hirsch; Giorgio Scagliotti; Tetsuya Mitsudomi; Rudolf M Huber; Yuichi Ishikawa; James Jett; Montserrat Sanchez-Cespedes; Jean-Paul Sculier; Takashi Takahashi; Masahiro Tsuboi; Johan Vansteenkiste; Ignacio Wistuba; Pan-Chyr Yang; Denise Aberle; Christian Brambilla; Douglas Flieder; Wilbur Franklin; Adi Gazdar; Michael Gould; Philip Hasleton; Douglas Henderson; Bruce Johnson; David Johnson; Keith Kerr; Keiko Kuriyama; Jin Soo Lee; Vincent A Miller; Iver Petersen; Victor Roggli; Rafael Rosell; Nagahiro Saijo; Erik Thunnissen; Ming Tsao; David Yankelewitz Journal: J Thorac Oncol Date: 2011-02 Impact factor: 15.609
Authors: Kyuichi Kadota; Jonathan Villena-Vargas; Jun-Ichi Nitadori; Camelia S Sima; David R Jones; William D Travis; Prasad S Adusumilli Journal: Ann Surg Oncol Date: 2015-01-22 Impact factor: 5.344
Authors: Kyuichi Kadota; Jun-Ichi Nitadori; Inderpal S Sarkaria; Camelia S Sima; Xiaoyu Jia; Akihiko Yoshizawa; Valerie W Rusch; William D Travis; Prasad S Adusumilli Journal: Cancer Date: 2012-10-23 Impact factor: 6.860
Authors: Kei Suzuki; Kyuichi Kadota; Camelia S Sima; Jun-ichi Nitadori; Valerie W Rusch; William D Travis; Michel Sadelain; Prasad S Adusumilli Journal: J Clin Oncol Date: 2012-12-26 Impact factor: 44.544
Authors: Katharina Leithner; Christoph Wohlkoenig; Elvira Stacher; Jörg Lindenmann; Nicole A Hofmann; Birgit Gallé; Christian Guelly; Franz Quehenberger; Philipp Stiegler; Freyja-Maria Smolle-Jüttner; Sjaak Philipsen; Helmut H Popper; Andelko Hrzenjak; Andrea Olschewski; Horst Olschewski Journal: BMC Cancer Date: 2014-01-25 Impact factor: 4.430
Authors: T Fukusumi; H Ishii; M Konno; T Yasui; S Nakahara; Y Takenaka; Y Yamamoto; S Nishikawa; Y Kano; H Ogawa; S Hasegawa; A Hamabe; N Haraguchi; Y Doki; M Mori; H Inohara Journal: Br J Cancer Date: 2014-05-29 Impact factor: 7.640
Authors: Jakub Żurawski; Patrycja Talarska; Mateusz de Mezer; Krzysztof Kaszkowiak; Michał Chalcarz; Katarzyna Iwanik; Jacek Karoń; Piotr Krokowicz Journal: Gastroenterol Hepatol Bed Bench Date: 2022
Authors: Noemi Pavo; Henrike Arfsten; Anna Cho; Georg Goliasch; Philipp E Bartko; Raphael Wurm; Claudia Freitag; Heinz Gisslinger; Gabriela Kornek; Guido Strunk; Markus Raderer; Christoph Zielinski; Martin Hülsmann Journal: Sci Rep Date: 2019-02-22 Impact factor: 4.379